| Date | Time | Source | Headline | Symbol | Company |
| 05/08/2024 | 1:05PM | iHub Newswire | FeaturedElement79 Gold Corp Successfully Closes Maverick Springs Option Agreement | | |
| 05/08/2024 | 7:20AM | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:IMUX | Immunic Inc |
| 05/08/2024 | 6:45AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:IMUX | Immunic Inc |
| 05/08/2024 | 6:30AM | PR Newswire (US) | Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update | NASDAQ:IMUX | Immunic Inc |
| 05/06/2024 | 6:30AM | PR Newswire (US) | Immunic to Participate in Investor and Scientific Conferences in May | NASDAQ:IMUX | Immunic Inc |
| 05/01/2024 | 6:30AM | PR Newswire (US) | Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update | NASDAQ:IMUX | Immunic Inc |
| 04/30/2024 | 6:30AM | PR Newswire (US) | Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation | NASDAQ:IMUX | Immunic Inc |
| 04/04/2024 | 6:30AM | PR Newswire (US) | Immunic to Host MS R&D Day and Participate in Investor Conferences in April | NASDAQ:IMUX | Immunic Inc |
| 03/20/2024 | 6:30AM | PR Newswire (US) | Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States | NASDAQ:IMUX | Immunic Inc |
| 03/08/2024 | 4:05PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:IMUX | Immunic Inc |
| 03/07/2024 | 6:30AM | PR Newswire (US) | Immunic to Participate in Investor and Scientific Conferences in March | NASDAQ:IMUX | Immunic Inc |
| 03/06/2024 | 9:52PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:IMUX | Immunic Inc |
| 03/06/2024 | 9:51PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:IMUX | Immunic Inc |
| 03/06/2024 | 9:51PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:IMUX | Immunic Inc |
| 03/06/2024 | 9:50PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:IMUX | Immunic Inc |
| 03/06/2024 | 9:50PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:IMUX | Immunic Inc |
| 03/06/2024 | 9:50PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:IMUX | Immunic Inc |
| 02/29/2024 | 6:30AM | PR Newswire (US) | Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024 | NASDAQ:IMUX | Immunic Inc |
| 02/22/2024 | 6:38AM | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] | NASDAQ:IMUX | Immunic Inc |
| 02/22/2024 | 6:35AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:IMUX | Immunic Inc |
| 02/22/2024 | 6:30AM | PR Newswire (US) | Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update | NASDAQ:IMUX | Immunic Inc |
| 02/15/2024 | 6:30AM | PR Newswire (US) | Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate Update | NASDAQ:IMUX | Immunic Inc |
| 02/14/2024 | 4:05PM | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:IMUX | Immunic Inc |
| 02/14/2024 | 8:47AM | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:IMUX | Immunic Inc |
| 02/14/2024 | 7:55AM | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:IMUX | Immunic Inc |
| 02/13/2024 | 4:36PM | Edgar (US Regulatory) | Form S-3 - Registration statement under Securities Act of 1933 | NASDAQ:IMUX | Immunic Inc |
| 02/05/2024 | 8:30AM | Edgar (US Regulatory) | Form DEF 14A - Other definitive proxy statements | NASDAQ:IMUX | Immunic Inc |
| 02/01/2024 | 6:30AM | PR Newswire (US) | Immunic to Participate in Investor and Scientific Conferences in February | NASDAQ:IMUX | Immunic Inc |
| 01/24/2024 | 5:05PM | Edgar (US Regulatory) | Form PRE 14A - Other preliminary proxy statements | NASDAQ:IMUX | Immunic Inc |
| 01/19/2024 | 4:07PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:IMUX | Immunic Inc |